PDF Cover

Iopromide Market

The market for Iopromide was estimated at $536 million in 2024; it is anticipated to increase to $744 million by 2030, with projections indicating growth to around $977 million by 2035.

Report ID:DS1802217
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Iopromide
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Iopromide Market Outlook

Revenue, 2024

$536M

Forecast, 2034

$924M

CAGR, 2025 - 2034

5.6%

The Iopromide industry revenue is expected to be around $566.3 million in 2025 and expected to showcase growth with 5.6% CAGR between 2025 and 2034. This substantial growth portrays the sustained importance and relevance of Iopromide in the global market. This dynamism is largely attributed to key driving factors such as its extensive use in diagnostic and medical imaging, technological advancements in healthcare, and amplified demand for effective and safe imaging agents in radiology. In addition, the ascent of enhanced healthcare infrastructure, coupled with a burgeoning patient population requiring imaging diagnostics, further underlines continued market interest in Iopromide.

Iopromide, also known as Ultravist,, classified as a nonionic, low-osmolar contrast medium, possesses certain unique features that make it a preferred choice in various clinical procedures. A standout attribute of Iopromide is its high tolerability and reliable safety profile. It is predominantly used in imaging diagnostics, intra-arterial procedures, intravenous urography, and CT scans.

Iopromide market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Iopromide Market Outlook

Market Key Insights

  • The Iopromide market is projected to grow from $536.3 million in 2024 to $925 million in 2034. This represents a CAGR of 5.6%, reflecting rising demand across Computed Tomography, Angiography, and Urography.

  • Bayer Healthcare is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Iopromide market and are expected to observe the growth CAGR of 3.6% to 5.4% between 2024 and 2030.

  • Emerging markets including Brazil, South Korea and Saudi Arabia are expected to observe highest growth with CAGR ranging between 6.4% to 7.7%.

  • Industry players are pushing the adoption of transitions like Expanding Applications in Diagnostic Imaging for future years due to existing low growth of 5.6% ; but are also expected to invest $21 million by 2030.

  • The Iopromide market is set to add $388 million between 2024 and 2034, with manufacturer targeting Angiography & Urography Application projected to gain a larger market share.

  • With

    advancements in medical imaging, and

    Increased Incidence of Chronic Diseases, Iopromide market to expand 72% between 2024 and 2034.

iopromide market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Iopromide - Country Share Analysis

Opportunities in the Iopromide

Avenues for growth lie in potential strategic collaborations between contrast agent manufacturers and healthcare facilities. Partnerships with hospitals and diagnostic centers can also help Iopromide manufacturers tap into a ready consumer base.

Growth Opportunities in North America and Asia-Pacific

With its advanced healthcare system, North America represents a significant market for Iopromide. The increasing prevalence of chronic diseases demanding diagnostic imaging has led to a surge in the use of contrast agents such as Iopromide. In addition, strong investment in medical research and development, along with established hospital networks, create a conducive environment for market growth. However, the intensity of competition in this region is high, with numerous established players such as Bayer and GE Healthcare adding to the competitive pressure. Key market drivers include the growing geriatric population, advancements in diagnostic imaging technologies, and increased use of personalized medicine.
In Asia-Pacific, the market for Iopromide is rapidly growing due to increasing healthcare expenditure and growing awareness about early disease detection. The presence of a large patient pool, amplified by the rapidly growing ageing population, is set to increase the demand for diagnostic tests in which Iopromide is used. However, fierce competition from local and international players, along with regulatory challenges, could pose potential hurdles. Key drivers in the Asia-Pacific region include increasing investments in healthcare infrastructure, rising incidence of chronic diseases, and the implementation of several government initiatives aimed at improving healthcare outcomes.

Market Dynamics and Supply Chain

01

Driver: Growing Demand for Advanced Imaging and Rising Incidence of Chronic Diseases

The global iopromide market is also significantly driven by the rising demand for advanced diagnostic imaging procedures. Computed tomography and angiography are also increasingly used in hospitals and diagnostic centers to detect cancers, cardiovascular diseases, and neurological conditions at early stages. As clinicians adopt sophisticated imaging systems, they require reliable low-osmolar, non-ionic contrast agents like iopromide to ensure high-resolution images with minimal patient discomfort. In parallel, the incidence of chronic diseases such as cancer, stroke, and heart disease continues to grow due to aging populations and lifestyle factors, prompting more frequent use of contrast-enhanced imaging. This dual growth in imaging utilization and chronic disease prevalence expands market opportunities for iopromide, particularly in regions with improving healthcare infrastructure and increased access to diagnostic services. Hospitals and outpatient imaging facilities increasingly integrate iopromide into standard protocols for enhanced diagnostic accuracy.
The evolution of low-osmolar, non-ionic contrast media also represents a pivotal driver for iopromide adoption. Innovations in molecular design have also reduced osmolality and improved tolerability compared to traditional ionic agents, resulting in fewer adverse reactions during diagnostic imaging. These advancements support broader clinical acceptance among radiologists and clinicians, who prioritize both image quality and patient safety. Improved contrast formulations enable higher patient throughput in CT and angiographic procedures, addressing operational needs in busy hospitals. As healthcare providers seek safer, more effective agents, iopromide’s refined profile strengthens its position in competitive imaging markets and supports sustained demand growth.
02

Restraint: Safety Concerns and Adverse Reactions Limiting Clinical Adoption

Despite its widespread use, iopromide’s growth is restrained by safety concerns related to iodine-based contrast agents. Adverse reactions such as allergic responses and potential nephrotoxicity in patients with impaired renal function reduce clinician willingness to use iopromide in vulnerable populations, particularly in geriatric and comorbid cases. These risks prompt healthcare providers to prefer alternative agents or non-contrast imaging modalities, lowering procedure volumes that rely on iopromide. For example, reports of hypersensitivity reactions can deter use in outpatient settings, reducing overall market demand and negatively impacting revenue growth. Such safety limitations influence decision-making at hospitals and diagnostic centers, restricting broader market expansion.
03

Opportunity: Untapped Market Potential and Technological Innovations

Iopromide, a non-ionic, water-soluble radiographic contrast agent, has significant untapped potential in emerging markets. Countries such as China, India, and Brazil, with rapidly expanding healthcare sectors and burgeoning middle-class populations, represent remarkable opportunities for Iopromide. In these nations, the rising prevalence of diseases requiring diagnostic imaging is set to intensify demand for contrast agents, underscoring Iopromides growth potential.
The incorporation of advanced technologies in radiographic imaging is poised to enhance Iopromide use. The advent of high-speed CT scanners and advancements in MRI technology necessitate the use of efficient contrast agents, providing ample room for Iopromides application. The ongoing technological evolution in radiographic imaging provides a solid base for Iopromides market expansion.
04

Challenge: High Costs and Stringent Regulatory Requirements Increasing Market Barriers

The iopromide market faces significant restraints from elevated production and compliance costs combined with rigorous regulatory environments. Manufacturers incur substantial expenses related to safety evaluations, quality certifications, and documentation, which slow product approvals and increase time-to-market. This is particularly challenging for smaller firms unable-to absorb high R&D and regulatory compliance costs, limiting their ability to innovate or compete. Additionally, the high cost of contrast agents and associated imaging procedures burdens healthcare budgets, especially in low- and middle-income regions, reducing access and dampening demand. For instance, constrained healthcare spending in developing markets restricts adoption of advanced imaging contrast media.

Supply Chain Landscape

1

Material Suppliers

Chemical Manufacturers AssociationSynoptica Ltd
2

Intermediate Producers

Sigma-Aldrich CorporationFagron Group BV
3

Product Manufacturers

Bayer HealthcareGE Healthcare
4

End-use

Diagnostic CentersHospitalsPharmaceutical Companies
Iopromide - Supply Chain

Use Cases of Iopromide in Computed Tomography & Urography

Computed Tomography : In computed tomography, iopromide is predominantly used as a non-ionic, low-osmolar iodinated contrast agent, typically in concentrations such as iopromide 300 or 370 mg iodine/mL. It is administered intravenously to enhance soft tissue contrast and vascular structures during CT scans of the brain, chest, abdomen, and trauma cases. The key advantage of iopromide in CT imaging lies in its favorable safety profile, characterized by reduced osmolality and lower incidence of adverse reactions compared to older ionic agents. Its rapid distribution and consistent image enhancement support high-throughput CT workflows, making it well suited for hospitals and diagnostic imaging centers managing large patient volumes.
Angiography : For angiography applications, high-concentration iopromide formulations such as iopromide 370 are most commonly used due to their ability to provide strong vascular opacification. The agent is injected intra-arterially to visualize coronary, cerebral, and peripheral blood vessels with high clarity. Iopromide’s low viscosity and non-ionic nature allow smooth catheter injection and reduce patient discomfort during complex interventional procedures. These characteristics are particularly valuable in cardiovascular and neurovascular angiography, where image precision directly influences clinical outcomes. The predictable hemodynamic behavior of iopromide supports its use in advanced angiographic techniques, reinforcing its preference among interventional radiologists in tertiary care hospitals.
Urography : In urography, iopromide is widely used for intravenous urography and CT urography to assess renal anatomy and urinary tract function. Medium-concentration iopromide formulations are typically selected to balance optimal contrast enhancement with renal safety. Its high water solubility enables rapid renal excretion, allowing clear visualization of kidneys, ureters, and bladder during sequential imaging phases. A major advantage in urography is its relatively low nephrotoxic potential compared to older contrast agents, supporting safer use in patients requiring detailed urinary system evaluation. This makes iopromide a reliable choice in both routine diagnostic and preoperative urological imaging.

Recent Developments

Recent developments in Ultravist reflect sustained emphasis on enhancing diagnostic imaging contrast media performance and safety. Manufacturers are refining low-osmolar, non-ionic formulations to support high-resolution computed tomography and angiography while minimizing adverse reactions. A key trend is integration with advanced imaging protocols that favor reduced iodine doses and better patient tolerability. Growing adoption in oncology and cardiovascular diagnostics underscores demand for reliable vascular and soft-tissue enhancement. Strategic focus on regulatory compliance and clinical validation further bolsters market competitiveness and long-term use.

December 2025 : Bayer announced FDA 510(k) clearance for its MEDRAD Centargo multi‑patient CT injector to support a wider range of compatible contrast agent presentations, including single‑dose vials of Ultravist (iopromide), enhancing flexibility for high‑throughput imaging suites and facilitating waste reduction and operational efficiency in radiology practices.
June 2023 : The U.S. Food and Drug Administration approved Ultravist (iopromide‑300 and ‑370) for use in contrast‑enhanced mammography (CEM), making it the only iodine‑based contrast agent indicated to visualize known or suspected breast lesions in adults as an adjunct to mammography or ultrasound.

Impact of Industry Transitions on the Iopromide Market

As a core segment of the Pharmaceutical industry, the Iopromide market develops in line with broader industry shifts. Over recent years, transitions such as Expanding Applications in Diagnostic Imaging and Advances in Nanotechnology Integration have redefined priorities across the Pharmaceutical sector, influencing how the Iopromide market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Expanding Applications in Diagnostic Imaging

Iopromides usage has been traditionally entrenched in the healthcare industry as a contrast material during Xrays and CT Scans. However, its application has now significantly broadened to include other diagnostic imaging techniques such as intravascular ultrasonography and magnetic resonance imaging . This transition has greatly enhanced the capability and accuracy of diagnostic imaging, leading to more precise diagnoses and better patient outcomes. The overall effect has been a surge in demand for Iopromide across the medical imaging field, propelling growth for pharmaceutical companies involved in producing the material.
02

Advances in Nanotechnology Integration

Advances in nanotechnology integration are reshaping the iopromide market by enabling the development of more efficient and targeted contrast agents. By using iopromide as a base material, pharmaceutical companies are engineering nanoscale formulations that improve tissue specificity and enhance image clarity while reducing overall iodine dosage. This transition supports safer diagnostic imaging, particularly in oncology and cardiovascular applications where precision is critical. For example, research into nanoparticle-based contrast systems has improved tumor imaging accuracy, directly influencing cancer diagnostics and treatment planning. Beyond radiology, these innovations are impacting drug delivery research and medical device development, as nanoscale contrast agents facilitate combined diagnostic and therapeutic applications. Overall, nanotechnology-driven advancements are expanding iopromide’s functional scope and strengthening its relevance across multiple healthcare industries.